Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26212331 | 0.87 | GAA (0.51) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL16140465 | 0.82 | HSD17B10 (0.47) | HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL27000233 | 0.78 | GRM4 (0.56) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL10137832 | 0.78 | TAAR1 (0.51) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL10174302 | 0.77 | TAAR1 (0.50) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL26210903 | 0.76 | TAAR1 (0.46) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL14159195 | 0.75 | TAAR1 (0.58) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL26731766 | 0.74 | TAAR1 (0.50) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL27000121 | 0.74 | TAAR1 (0.44) | TAAR1HSD17B10ALDH1A1CASP1GLA | |
| SCHEMBL19141813 | 0.73 | TAAR1 (0.56) | TAAR1HSD17B10ALDH1A1CASP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |